We are delighted to welcome Sofia Helgesson as BioLamina’s new Chief Financial Officer.

Sofia joins us with deep financial expertise across healthcare and life sciences, and experience from Advent International, Jacobs Holding, Altor, and J.P. Morgan. She is energized by entrepreneurial, fast-moving environments — a great fit for BioLamina’s mission to advance regenerative medicine through high-quality, laminin-based cell culture solutions.

We also want to thank Magnus Åkerhielm for his outstanding contribution as CFO. Magnus has been instrumental in building BioLamina’s financial foundation, and we are glad he will continue to support the company as a Senior Advisor.

Please join us in welcoming Sofia to the team!

About BioLamina 

BioLamina is a biotechnology company with deep expertise in matrix biology and cell culture. The company develops and manufactures laminin-based cell culture substrates that enable reliable growth and differentiation of pluripotent stem cells and other primary cells. 

By providing defined, high-quality and scalable cell culture solutions, BioLamina supports researchers and developers in advancing cell therapies and improving the accuracy of cell-based models used in drug discovery and development. 

Biolaminin® substrates are full-length, chemically defined and animal origin-free human recombinant laminins, designed for controlled cell culture systems and used in cell therapy development, including phase I–III clinical trials across major regulatory jurisdictions. BioLamina is headquartered in Stockholm, Sweden. 

Press contact:  

Sandra Falci, Interim Marketing Manager | sandra.falci@biolamina.com